Could an AI-Designed pill take on Hard-to-Treat cancers?

NCT ID NCT06445517

Recruiting now Disease control Sponsor: InSilico Medicine Hong Kong Limited Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body processes it, while also looking for any early signs that it might shrink tumors or control the disease. The study is the first time ISM8207 is being given to humans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental oral drug called ISM8207
What this could lead to: If safe and effective, ISM8207 could offer a new treatment option for people with advanced solid tumors or B-cell lymphoma who have run out of standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 60 participants, so the drug may prove unsafe or ineffective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma neoplasm relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS RELAPSED/REFRACTORY B-CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Shanghai Jiao Tong University School of Medicine-Ruijin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, China
Tianjin Medical University Cancer Institute&Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.